Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.

Gastroenterology - 1 Apr 2006

Taliani Gloria, Gemignani Giulia, Ferrari Carlo, Aceti Antonio, Bartolozzi Dario, Blanc Pier Luigi, Capanni Marco, Esperti Francesco, Forte Paolo, Guadagnino Vincenzo, Mari Terenzio, Marino Nicoletta, Milani Stefano, Pasquazzi Caterina, Rosina Floriano, Tacconi Danilo, Toti Mario, Zignego Anna Linda, Messerini Luca, Stroffolini Tommaso

Abstract excerpt

BACKGROUND & AIMS: Inadequate data are available about retreatment of nonresponders to interferon (IFN) and ribavirin. Thus, this study evaluated the efficacy and tolerability of a 48-week therapy with pegylated IFN-alpha-2b plus high-dose ribavirin in patients who have failed to respond to the combination. Treatment up to 48 weeks also in patients who have failed to clear hepatitis C virus (HCV) RNA by week 24...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to gamma-Glutamyltransferase
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Interferons

Share to Polyethylene Glycols

Share to Retreatment

Share to Ribavirin

Share to Treatment Failure

Source

Identifiers

PMID: 16618404
DOI: 10.1053/j.gastro.2006.02.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.PMID 16618404Read ↗

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?Semantic proximity Read ↗

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.Semantic proximity Read ↗

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.Semantic proximity Read ↗

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.Semantic proximity Read ↗

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.Semantic proximity Read ↗

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.Semantic proximity Read ↗

Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.Semantic proximity Read ↗

Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.Semantic proximity Read ↗

Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.